P
Paul N. Meyer
Researcher at University of Nebraska Medical Center
Publications - 18
Citations - 1820
Paul N. Meyer is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Diffuse large B-cell lymphoma & CHOP. The author has an hindex of 11, co-authored 18 publications receiving 1667 citations. Previous affiliations of Paul N. Meyer include Pennsylvania State University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson,Graham W. Slack,Kerry J. Savage,Joseph M. Connors,Susana Ben-Neriah,Sanja Rogic,David W. Scott,King Tan,Christian Steidl,Laurie H. Sehn,Wing C. Chan,Javeed Iqbal,Paul N. Meyer,Georg Lenz,George E. Wright,Lisa M. Rimsza,Carlo Valentino,Patrick Brunhoeber,Thomas M. Grogan,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,Dennis D. Weisenburger,Elias Campo,Andreas Rosenwald,German Ott,German Ott,Jan Delabie,Christina Holcroft,Elaine S. Jaffe,Louis M. Staudt,Randy D. Gascoyne +31 more
TL;DR: Assessment of MYC and BCL2 expression by IHC represents a robust, rapid, and inexpensive approach to risk-stratify patients with DLBCL at diagnosis.
Journal ArticleDOI
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer,Kai Fu,Timothy C. Greiner,Lynette M. Smith,Jan Delabie,Randy D. Gascoyne,German Ott,Andreas Rosenwald,Rita M. Braziel,Elias Campo,Julie M. Vose,Georg Lenz,Louis M. Staudt,Wing C. Chan,Dennis D. Weisenburger +14 more
TL;DR: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.
Journal ArticleDOI
BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-Cell Lymphoma Treated with CHOP-like therapy and Rituximab
Javeed Iqbal,Paul N. Meyer,Lynette M. Smith,Nathalie A. Johnson,Julie M. Vose,Timothy C. Greiner,Joseph M. Connors,Louis M. Staudt,Lisa M. Rimsza,Elaine S. Jaffe,Andreas Rosenwald,German Ott,Jan Delabie,Elias Campo,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,Randy D. Gascoyne,James O. Armitage,Dennis D. Weisenburger,Wing C. Chan +20 more
TL;DR: Although rituximab has benefited patients in both DLBCL subgroups, the BCL2(+)GCB-DLBCL seems to receive less benefit from this treatment and may require other novel therapeutic intervention.
Journal ArticleDOI
Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults.
TL;DR: Adult patients with translocation carcinoma associated with Xp11.2 translocations followed a rapidly terminal course, with a mean survival of 18 months after diagnosis (range, 10-24 months), and all cases showed strong nuclear positivity for TFE3.
Journal ArticleDOI
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Paul N. Meyer,Kai Fu,Timothy C. Greiner,Lynette M. Smith,Jan Delabie,Randy D. Gascoyne,German Ott,Andreas Rosenwald,Rita M. Braziel,Elias Campo,Julie M. Vose,Georg Lenz,Louis M. Staudt,Wing C. Chan,Dennis D. Weisenburger +14 more
TL;DR: Investigation of immunostains for 2 stromal cell markers revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin, determining a subgroup of patients with ABC DLBCL who have significantly longer survival.